About Inhance
The
International
Head
and
Neck
Cancer
Epidemiology (INHANCE)
Consortium was established in 2004, based on the collaboration of
research groups leading large molecular epidemiology studies of
head & neck cancer that are on-going or have been recently completed.
When taken collectively, questionnaire data on over 25,000 cases
& 33,000 controls, and biological samples from a majority of
the study population would be available. These studies have been
conducted in various regions of the world.
Worldwide, an estimated half a million head & neck cancer cases
and 300,000 deaths due to head & neck cancer occurred in the
year 2002. Head and neck cancers are a related group of cancers
that involve the oral cavity, pharynx and larynx. While it is well-established
that tobacco and alcohol account for at least 75% of head &
neck cancers, important etiologic questions remain to be addressed:
(i) the role of low penetrance genetic susceptibility factors (e.g.
SNPs) and their interactions with environmental factors, (ii) etiology
in rare subgroups including young age at onset, and nonsmokers and
nondrinkers, (iii) the effect of human papillomavirus (HPV), particularly
with respect to cancer subsite.
As a first step for the consortium, we plan to conduct pooled analyses
of lifestyle risk factors such as alcohol beverage type and concentration,
and also pooled analyses in rare groups such as early onset head
and neck cancer cases, and nonsmokers/nondrinkers. Working groups
have been formed for research topics such as HPV, genetics/ DNA
repair, nonsmokers/nondrinkers, early onset cases and occupational
factors.
Future directions for the consortium will be to coordinate genotyping from a list of priority SNPs and to assess the effect of HPV infection. We anticipate that the INHANCE consortium will be a major step toward improving our understanding of the causes and mechanisms of head & neck cancers and the beginning of a long-standing cooperation.